Description of Medical ServiceTesting of tumour material in patients with non-small cell lung cancer (NSCLC) to detect chromosomal rearrangements in the ROS1 gene to determine eligibility for treatment with Xalkori (crizotinib) through the PBS.
PBS subsidy will also be sought for Xalkori (crizotinib) for the treatment of patients with ROS1-rearranged NSCLC.
Description of Medical ConditionPatients with non-squamous non-small cell lung cancer (NSCLC).
Reason for ApplicationNew MBS item
Medical Service TypeInvestigative
Previous Application NumberNot Applicable
Application FormApplication Form (PDF 314 KB)
Application Form (Word 559 KB)
PICO ConfirmationPICO Confirmation (PDF 330 KB)
PICO Confirmation (Word 204 KB)
Public Summary DocumentPublic Summary Document (PDF 320 KB)
Public Summary Document (Word 120 KB)
Meetings for this Application
PASC8 December 2016
ESC5 October 2017
MSAC23 November 2017
26-27 July 2018